As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.
13 Analysts have issued a CureVac N.V. forecast:
13 Analysts have issued a CureVac N.V. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 588 588 |
675%
675%
|
|
| Gross Profit | 558 558 |
613%
613%
|
|
| EBITDA | 263 263 |
185%
185%
|
|
| EBIT (Operating Income) EBIT | 240 240 |
172%
172%
|
|
| Net Profit | 223 223 |
170%
170%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
| Head office | Netherlands |
| CEO | Alexander Zehnder |
| Employees | 904 |
| Founded | 2020 |
| Website | www.curevac.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


